CORRECTED-Becton Dickinson cuts annual profit forecast to reflect sale of biosciences and diagnostics unit

Reuters
02/09
CORRECTED-Becton Dickinson cuts annual profit forecast to reflect sale of biosciences and diagnostics unit

Corrects per-share comparable profit to $2.81 from $3.27 in paragraph 8 and revenue estimates to $5.15 billion from $5.33 billion in paragraph 10. Also corrects the paragraphs to say the company beat expectations and did not miss.

Feb 9 (Reuters) - Medical device maker Becton Dickinson BDX.N cut its profit forecast for fiscal year 2026 on Monday, adjusting its outlook to account for the separation and sale of its biosciences and diagnostics unit to lab equipment manufacturer Waters WAT.N.

Becton now expects adjusted earnings per share of $12.35 to $12.65 in fiscal year 2026, lower than its prior forecast of $14.75 to $15.05.

Shares of the company fell nearly 5% in premarket trading.

The new guidance includes adjustments solely to reflect the corporate overhead migrating to Waters Corp, transition services income and expected benefit from the deal proceeds, the company said.

The transaction is expected to close on Monday, Becton and Waters said, with the lab equipment maker calling the addition to its business "transformative."

The deal was announced in July last year and will expand Waters' footprint in clinical and diagnostic applications.

"With the life sciences business separation now completed, we believe BD will have sharpened strategic focus on high-growth MedTech end markets. But its growth recovery back to mid-single-digits is yet to be proven out," said RBC Capital Markets analyst Shagun Singh.

For the quarter ended December 31, 2025, Becton reported adjusted earnings per share of $2.91, above analysts' estimates of $2.81, according to LSEG data.

Its quarterly revenue of $5.25 billion also beat estimates of $5.15 billion, but grew 1.6% from a year earlier driven by growth in the Connected Care business. Revenue from the advanced patient monitoring segment was up 5.5% at $1.13 billion, while revenue from Interventional, which provides surgical solutions, was up 5.8% at $1.33 billion.

Revenue from the company's life sciences business fell 8.3% during the quarter to $766 million. Excluding this segment, which is being taken over by Waters, Becton's revenue rose 3.5% to $4.49 billion.

(Reporting by Sahil Pandey in Bengaluru; Editing by Jonathan Ananda)

((Sahil.Pandey@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10